StockData
Fate Therapeutics Inc logo

Fate Therapeutics Inc (FATE) stock

FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3024% below fair value
$1.02−0.12 (-10.53%)

Close on Nov 17, 2026Market cap $122.22MP/E –Yield –

Fate Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Fate Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$133.59M. For fiscal 2025 it was -$147.70M. The highest annual figure on record is -$13.29M in fiscal 2011.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$147.70M–
FY2024Dec 31, 2024-$210.28M–
FY2023Dec 31, 2023-$190.51M–
FY2022Dec 31, 2022-$308.39M–
FY2021Dec 31, 2021-$216.99M–
FY2020Dec 31, 2020-$128.09M–
FY2019Dec 31, 2019-$100.73M–
FY2018Dec 31, 2018-$67.09M–
FY2017Dec 31, 2017-$42.13M–
FY2016Dec 31, 2016-$31.96M–
FY2015Dec 31, 2015-$27.78M–
FY2014Dec 31, 2014-$24.90M–
FY2013Dec 31, 2013-$17.68M–
FY2012Dec 31, 2012-$13.56M–
FY2011Dec 31, 2011-$13.29M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$31.13M–
Q1 FY2026Mar 31, 2026-$33.00M–
Q4 FY2025Dec 31, 2025-$34.72M–
Q3 FY2025Sep 30, 2025-$34.74M–
Q2 FY2025Jun 30, 2025-$36.97M–
Q1 FY2025Mar 31, 2025-$41.28M–
Q4 FY2024Dec 31, 2024-$61.75M–
Q3 FY2024Sep 30, 2024-$52.38M–
Q2 FY2024Jun 30, 2024-$45.08M–
Q1 FY2024Mar 31, 2024-$51.07M–
Q4 FY2023Dec 31, 2023-$48.08M–
Q3 FY2023Sep 30, 2023-$51.28M–
Q2 FY2023Jun 30, 2023-$62.57M–
Q1 FY2023Mar 31, 2023-$28.59M–
Q4 FY2022Dec 31, 2022-$64.42M–
Q3 FY2022Sep 30, 2022-$86.39M–
Q2 FY2022Jun 30, 2022-$83.11M–
Q1 FY2022Mar 31, 2022-$74.47M–
Q4 FY2021Dec 31, 2021-$69.38M–
Q3 FY2021Sep 30, 2021-$54.62M–
Q2 FY2021Jun 30, 2021-$46.78M–
Q1 FY2021Mar 31, 2021-$46.21M–
Q4 FY2020Dec 31, 2020-$33.40M–
Q3 FY2020Sep 30, 2020-$31.49M–
Q2 FY2020Jun 30, 2020-$28.71M–
Q1 FY2020Mar 31, 2020-$34.49M–
Q4 FY2019Dec 31, 2019-$29.08M–
Q3 FY2019Sep 30, 2019-$27.12M–
Q2 FY2019Jun 30, 2019-$24.08M–
Q1 FY2019Mar 31, 2019-$20.45M–
Q4 FY2018Dec 31, 2018-$16.74M–
Q3 FY2018Sep 30, 2018-$16.69M–
Q2 FY2018Jun 30, 2018-$19.61M–
Q1 FY2018Mar 31, 2018-$14.05M–
Q4 FY2017Dec 31, 2017-$12.24M–
Q3 FY2017Sep 30, 2017-$10.34M–
Q2 FY2017Jun 30, 2017-$9.57M–
Q1 FY2017Mar 31, 2017-$9.97M–
Q4 FY2016Dec 31, 2016-$7.65M–
Q3 FY2016Sep 30, 2016-$8.39M–

More Fate Therapeutics figures

See a number that looks wrong?